Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.43 |
| ▸ | HTR2C | P28335 | 11/20 | 0.43 |
| ▸ | HTR2B | P41595 | 10/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6532681 | 0.86 | HTR2C (0.49) | HTR2AHTR2CHTR2BPKMDRD1 | |
| SCHEMBL2365632 | 0.84 | ADRA2A (0.37) | — | |
| SCHEMBL6631310 | 0.84 | FGFR4 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL2365770 | 0.79 | TNFRSF1A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL6650634 | 0.75 | ALDH1A1 (0.39) | HTR2AHTR2CDRD1 | |
| SCHEMBL2365631 | 0.75 | DRD2 (0.40) | HTR2AHTR2CDRD1DRD5 | |
| SCHEMBL2477900 | 0.75 | HTR2A (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL1907864 | 0.74 | ADRA2A (0.37) | HTR2AHTR2C | |
| SCHEMBL2369023 | 0.73 | HTR2A (0.48) | HTR2AHTR2CHTR2BDRD1DRD5 | |
| SCHEMBL2365900 | 0.72 | HTR2A (0.51) | HTR2AHTR2CMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |